

## **Briefing Material**

for 2<sup>nd</sup> quarter ended Jun. 30, 2021

Aug. 20, 2021

NAKANISHI INC.

#### Disclaimer

The information presented in these materials contains forward-looking statements about future business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from expectations and the projections presented in these materials due to changes in the global economy and fluctuations in foreign currency exchange rates and so on.



## Contents

Consolidated Financial Results for FY2021 Q2	3
Consolidated Financial Forecast for FY2021 (Revised on August 6 <sup>th</sup> )	<b>1</b> 1
Overviews of Each Segments and Future Initiative	14

# FY2021 Q2 Consolidated Financial Results



### **Consolidated Performance**

M of JPY	FY2021 Q2 Actual	FY2020 Q2 Actual	YoY Comparison	FY2021 Forecast Upward revision on May 7th	Ratio to the Forecast
Net sales	23,014	13,689	+68.1 %	19,792	+16.3 %
Gross Profits	13,914	7,846	+77.3 %	11,895	+17.0 %
Ratio to net sales	60.5 %	57.3 %	+3.2 pt	60.1 %	+0.4 pt
Operating Income	7,646	2,392	+219.6 %	5,685	+34.5 %
Ratio to net sales	33.2 %	17.5 %	+15.7 pt	28.7 %	+4.5 pt
Ordinary Income	7,423	2,490	+198.1 %	6,183	+20.1 %
Ratio to net sales	32.3 %	18.2 %	+14.1 pt	31.2 %	+1.0 pt
Profit attributable to owners of parents	5,366	1,858	+188.7 %	4,579	+17.2 %
Ratio to net sales	23.3 %	13.6 %	+9.7 pt	23.1 %	+0.2 pt
E P S (JPY)	61.93	21.45		52.85	<del>-</del>

#### **Currency rate**


Against the US dollar (JPY)	107.74	108.43	-0.69	105.00	+2.74
Against the EURO (JPY)	129.96	119.85	+10.11	123.00	+6.96

- Forex impact: Net sales +668M of JPY (vs FY2020 Q2 Actual) , +1,115M of JPY (vs FY2021 Q2 Forecast)
- Forex sensibility: Fluctuations in annual sales due to the depreciation of the yen (per one yen)
   Against USD: Increase of 80M of JPY
   Against EURO: Increase of 78M of JPY



### Change in net sales by business segment

M of JPY




### ▶ Net sales by business segment

	FY2020 Q2 Actual	Change	
Dental	11,666	19,874	+8,207
Industrial	1,406	1,702	+296
Others	616	768	+151
Forex impact	-	+668	+668
Total	13,689	23,014	+9,324



### Dental segment; Change in net sales by region

M of JPY



### ▶ Net sales of Dental segment by region


	FY2020 Q2 Actual	FY2021 Q2 Actual	Change
Europe	4,123	6,029	+1,905
Japan	2,296	4,621	+2,324
North America	1,479	3,298	+1,818
Asia	1,944	2,958	+1,013
Others	1,821	2,966	+1,145
Forex impact	-	+656	+656
Total	11,666	20,530	+8,864



### Industrial segment; Change in net sales by region

M of JPY

Net sales



### ▶ Net sales of Industrial segment by region

	FY2020 Q2 Actual	FY2021 Q2 Actual	Change
Japan	505	544	+39
Asia	330	490	+160
North America	355	433	+77
Europe	214	230	+15
Others	0	3	+2
Forex impact	-	-2	-2
Total	1,406	1,699	+293

Net sales




### Change in operating income



< Exchange rate >

USD: 108.43JPY → 107.74JPY

EURO : 119.85JPY → 129.96JPY





### **Consolidated Balance Sheet**

M of JPY	As of June 30, 2021	As of Dec.31, 2020	Change	Note	
Total assets	89,933	82,470	+7,462	· Cash and deposits	+6,461
<ul> <li>Notes and accounts receivable-trade</li> </ul>	5,791	5,158	+633		
- Inventories	10,503	10,604	-100	<ul><li>Merchandise and finished goods</li><li>Work in process</li><li>Raw materials and supplies</li></ul>	+269 -141 -227
Liabilities	8,727	6,198	+2,528	<ul><li>Accounts payable-trade</li><li>Other current liabilities</li></ul>	+377 +1,887
- Loans payable	100	100	_		
Net assets	81,206	76,272	+4,934		
- Retained earnings	81,502	77,435	+4,067		
Return on equity	13.0 %	8.7 %	+4.3 Pt	FY2020 Q2: 5.1%	
Return on assets	17.7 %	10.8 %	+6.9 Pt	FY2020 Q2: 6.4%	

	FY2021 Q2 Actual	FY2020 Q2 Actual	Change	Note
Capital Investments	575	611	-36	
Depreciation Expenses	853	838	+14	



### FY2021 Q2 Net sales figure

### (Including Forex impact)

M of JPY			Japan	Export sub total	Europe	North America	Asia	Others	Total
	FY2020	) Q2 Actual	2,296	9,370	4,123	1,479	1,944	1,821	11,666
Dental	FY2021	I Q2 Actual	4,621	15,909	6,496	3,287	3,130	2,995	20,530
2011101		Amount	+2,324	+6,539	+2,372	+1,807	+1,185	+1,173	+8,864
	YoY	Ratio	+101.2%	+69.8%	+57.5%	+122.1%	+61.0%	+64.4%	+76.0%
	FY2020	) Q2 Actual	505	901	214	355	330	0	1,406
Industrial	FY2021	I Q2 Actual	544	1,155	230	430	490	3	1,699
	YoY	Amount	+39	+254	+15	+75	+160	+2	+293
		Ratio	+7.8%	+28.2%	+7.4%	+21.1%	+48.5%	+296.0%	+20.9%
FY202		Q2 Actual	394	222	64	95	56	5	616
Others	FY2021	I Q2 Actual	438	345	132	122	77	11	783
	YoY	Amount	+43	+122	+68	+26	+21	+6	+166
	101	Ratio	+11.1%	+55.3%	+106.0%	+27.9%	+38.8%	+106.9%	+27.0%
	FY202	0 Q2 Actual	3,196	10,493	4,402	1,931	2,331	1,828	13,689
Total	FY202	1 Q2 Actual	5,604	17,409	6,859	3,840	3,698	3,010	23,014
	VeV	Amount	+2,408	+6,916	+2,457	+1,909	+1,367	+1,182	+9,324
	YoY	Ratio	+75.3%	+65.9%	+55.8%	+98.9%	+58.7%	+64.7%	+68.1%

# Consolidated Financial Forecast for FY2021



### Consolidated Financial Forecast for FY2021 (Revised on Aug. 6)


M of JPY	FY2021 Forecast Upward revision on Aug. 6 <sup>th</sup> .	FY2020 Actual	Change	Note
Net Sales	41,661	33,055	+26.0 %	
Gross Profits	25,597	19,731	+29.7 %	
Ratio to net sales	61.4 %	59.7 %	+1.8 Pt	
Operating Income	13,001	8,542	+52.2 %	
Ratio to net sales	31.2 %	25.8 %	+5.4 pt	
Ordinary Income	12,988	8,627	+50.5 %	
Ratio to net sales	31.2 %	26.1 %	+5.1 pt	
Profit attributable to owners of parents	9,338	6,455	+44.7 %	
Ratio to net sales	22.4%	19.5 %	+2.9 pt	
E P S (JPY)	108.52	74.49	_	
Capital Investments	2,250	1,163	+1,087	
Depreciation Expenses	1,781	1,759	+22	
Assumed Currency rate				
Against the US dollar (JPY)	105.00	106.67	-1.67 (Stronger JPY)	Forex sensibility: Annual net sales can fluctuate 54M of JPY per one JPY.
Against the EURO (JPY)	125.00	122.01	+2.99 (Weaker JPY)	Forex sensibility: Annual net sales can fluctuate 86M of JPY per one JPY.

### **Shareholder Return Policy and Transition**

### Shareholder return policy

We position the return of profits to our shareholders as one of the important management issues; therefore, we plan to enhance business foundation and promote investment in growth areas properly and proactively, as well as to return profits to shareholders in a well-balanced manner.

We endeavor to perform flexible acquisition of treasury stock and stable and continuous dividend increase with considering retained earnings required for future growth investment, and setting the standard for medium-term profit return as a total return ratio of 50%.




# Overviews of Each Segments and Future Initiative



### History of Consolidated Net Sales


A baseline of global sales rose due to expansion of global market share and needs for infection prevention measures (purchase of sterilizers and additional handpieces) in the field of dental practices.





### **Global Trend of Net Sales**

- Q1: Increased in sales due to domestic special demand by subsidy and sales expansion in the European market.
- **Q2**: Increased in sales due to the continuous strong European market and sales recovery in North America and developing countries.



### **Basic Strategy of FY2021**

## Trend of dental products market

Growing needs for infection prevention measures worldwide

Demand recovery for implant treatment and preventive dentistry



## **Basic strategy of FY2021**


Expand sales of main product handpieces and sterilizers

Expand sales of preventive dentistry products and implant treatment devices

### **Construction of New Plant (A1+)**

## Increase production aiming at net sales of 50 billion JPY as stated in our Med term Management Plan "NV2025"

- Start construction (schedule) November 2021
- Completion (schedule) June 2022
- Total amount of investment: About 1.8 billion JPY



[A1: Current Production Plant] 12,000m + [A1+: New Production Plant] 5,500m

### **Dental Business Market Status 1/3**

#### Measures for 2<sup>nd</sup> half Overview of 1st half Market **Net sales** Although activity restrictions Expand sales of "Surgic outlook continued, sales of local Pro2", which is a new **6.49** B JPY subsidiaries increased significantly device for implant **Europe** capturing strong demand at most. treatment, to each European countries, as well YoY OFM Business also recovered as our main product +57.5% significantly. handpieces. The sales decrease expected after A reactional decline in **Net sales** Market April was eased since a part of the demand from 2H is assumed outlook subsidy for preventing the spread 4.62B JPY since the subsidies from the of infection was extended. government has ended. Japan The recovery of OEM business YoY Expand sales of sterilizers became clear and it contributed and our main product +101.2% to a significant increase in sales in handpieces for dentistry. this term.

### **Dental Business Market Status 2/3**

#### Measures for 2<sup>nd</sup> half Overview of 1st half Capture demand of shifting **Net sales** Market Sales of own brand were strong, to the electric motors at outlook which led significant growth in 3.28<sub>B JPY</sub> most. net sales of local subsidiaries. North America Enhance approaching to Inventory adjustments by major YoY dental universities and OEMs have progressed, and DSO, and promote +122.1% orders have recovered steadily. expanding market share. -Sales of Chinese subsidiary grew steadily and sales increased Further enhancements of the **Net sales** Market significantly due to the end of the sales system of Chinese 3.13B JPY COVID-19 pandemic. subsidiary, and promote outlook -Sales of Korean subsidiary grew developing and expanding steadily. the agency network. **Asia** Sales recovered by capturing Assume the market remains YoY reactionary demand from refraining to be severe condition in the from buying although the influence of Asian countries due to the +61.0% the COVID-19 pandemic remains spread of the Delta variant.

in Asian countries.

### **Dental Business Market Status 3/3**

	C	Overview of 1st half	Mea	asures for 2 <sup>nd</sup> half
Middle East		<ul> <li>Sales increased due to additional orders from the acquired bid and capturing rebound demand from refraining from buying.</li> </ul>	Market outlook	<ul> <li>Some dental exhibitions are to be resumed. Attend them while keep performing online activities.</li> </ul>
South America	Net sales 2.99BJPY	<ul> <li>Increased advantages of the brand in the local market due to withdrawal of competitors. Sales recovered significantly due to the first purchase by new agents.</li> </ul>	Cutiook	<ul> <li>Promote sales expansion of our main product handpieces and implant related products.</li> </ul>
Russia	YoY +64.4%	<ul> <li>The dental market has been normalized and sales increased although the impact of the COVID-19 pandemic remained.</li> </ul>	Market outlook	<ul> <li>Solidify the No. 1 share in the region by localizing Moscow office and enhancing after-sales service.</li> </ul>
Australia		The government's tax incentives have been successful, and the willingness to make capital investment in dental clinics has increased. Sales increased by capturing those demands.	Market outlook	<ul> <li>Promote sales expansion of handpieces, sterilizers, and implant related products.</li> </ul>



### **Dental Business Topics**

## Aim for further expand of market share by expanding sales of highly competitive new products

Surgical micromoter system

## **Surgic Pro2**

On sale in Europe

Dental handpiece

### Ti-Max Z micro

Available in Sep. in Europe



- \*New product: world-class implant treatment device
- \*Improved functionality and safety with smaller and lighter design
- \*Start full promotion, marketing and sales in Europe

This product is a flagship product, and dominates the top sales in the product lineup. It is planned to be promoted in other regions than Europe.



- \*This is a flagship model of titanium body
- \*Realizes high torque with it's small head
- \*Also equipped with our original infection prevention systems "Clean Head System"

It is planned to be launched in September for European market.



### **Industrial Business Outline**

## Demand in the manufacturing industry recovered, and sales grew after April

### Overview of FY2021 1H

- Strong orders from Asian markets, especially from China
   Capital investment in 5G-related area and automobile industry is strong
- Market conditions have improved except from China after April, and sales have increased in all regions, including Japan, North America, and Europe etc.

### Measures for FY2021 2H

- Develop sales activities proactively towards mainly manufacturing industry, where the willingness for making capital investments is recovering
- Launch new products "CTS-3030" and "Sonic Cutter ZERO"



### **Industrial Business Topics**

### **New Products**

Coolant Through Spindle

CTS-3030

Launched on Jul.




A new product of a compact and high-speed rotary spindle, which can eject coolant from the tip of a drill during processing.

Time required for drilling process can be reduced significantly with a spindle motor unit that can be mounted on a small CNC lathe.

Ultrasonic cutter

### **Sonic Cutter ZERO**

Launched on Aug.



A new product of high-performance cutter that utilizes the amplitude of ultrasonic waves.

It exhibits its power when cutting, forming a window, and deburring of various thin materials such as cloth, plastic, and urethane.



### **Medical Business Outline**

## Market conditions have improved significantly, although the effects of the COVID-19 pandemic remain

### Overview of FY2021 1H

**Japan:** Double-digit increase in sales compared to the same period of the previous year due to the

success of sales promotion of existing customers and strengthening of sales to orthopedics.

**Europe:** The recovery of especially Italy and Spain were remarkable. Sales of both unit body and

disposables increased.

N. America: Acquisition of large-scale project by strengthening customer relations such as holding

hands-on course. Sales reached more than triple than that one from the same period of the

previous year.

Asia: Sales was recovered by capturing rebound demand from refraining from buying while the

impact of the COVID-19 pandemic remained.

### Measures for FY2021 2H

**Japan**: Promote customer development with the popular new product "P300 Attachment".

**Europe:** Promote sales activities with a view to full-scale recovery in each European market with

keeping close communication with local agents.

N. America: Aim for further expansion of sales by enhancing sales activities to general hospitals and

developing sales partners.

Asia: Aim for sales expansion with especially sales activities of new products although demand

recovery remain to be slow except for China.



### **Medical Business Topics**

## Enhance customer contact through product training sessions






Hands-on course at The University of Kansas in the U.S.A.

Endoscopic spine surgery Cadaver Workshop at Khoo Tech Puat Hospital in Singapore



### **Sustainability Report**



We have issued "Sustainability Report 2021". Please refer to our ESG initiatives.

https://en.nakanishi-inc.jp/sustainability/report/

